Best treatment option for patients with refractory aggressive B-cell lymphoma in the CAR-T cell era: real-world evidence from GELTAMO/GETH Spanish groups was written by Bastos-Oreiro, Mariana;Gutierrez, Antonio;Reguera, Juan Luis;Iacoboni, Gloria;Lopez-Corral, Lucia;Terol, Mara Jose;Ortiz-Maldonado, Valentin;Sanz, Jaime;Guerra-Dominguez, Luisa;Bailen, Rebeca;Mussetti, Alberto;Abrisqueta, Pau;Hernani, Rafael;Luzardo, Hugo;Sancho, Juan-Manuel;Delgado-Serrano, Javier;Salar, Antonio;Grande, Carlos;Bento, Leyre;de Villambrosa, Sonia Gonzalez;Garcia-Belmonte, Daniel;Sureda, Anna;Perez-Martinez, Antonio;Barba, Pere;Kwon, Mi;Garcia-Sancho, Alejandro Martin. And the article was included in Frontiers in Immunology in 2022.Formula: C16H21Cl2N3O2 The following contents are mentioned in the article:
Real-world evidence comparing the efficacy of chimeric antigen receptor (CAR) T-cell therapy against that of the previous standard of care (SOC) for refractory large B-cell lymphoma (LBCL) is scarce. We retrospectively collected data from patients with LBCL according to SCHOLAR-1 criteria treated with com. CAR T-cell therapy in Spain (204 patients included and 192 treated, 101 with axicabtagene ciloleucel [axi-cel], and 91 with tisagenlecleucel [tisa-cel]) and compared the results with a historical refractory population of patients (n = 81) obtained from the GELTAMO-IPI study. We observed superior efficacy for CAR-T therapy (for both axi-cel and tisa-cel) over pSOC, with longer progression-free survival (PFS) (median of 5.6 vs. 4-6 mo, p ≤ 0.001) and overall survival (OS) (median of 15 vs. 8 mo, p < 0.001), independently of other prognostic factors (HR: 0.59 (95% CI: 0.44-0.80); p < 0.001 for PFS, and 0.45 (95% CI: 0.31-0.64) for OS). Within the CAR-T cohort, axi-cel showed longer PFS (median of 7.3 vs. 2.8 mo, resp., p = 0.027) and OS (58% vs. 42% at 12 mo, resp., p = 0.048) than tisa-cel. These differences were maintained in the multivariable anal. On the other hand, axi-cel was independently associated with a higher risk of severe cytokine release syndrome and neurotoxicity. Our results suggest that the efficacy of CAR-T cell therapy is superior to pSOC in the real-world setting. Furthermore, axi-cel could be superior in efficacy to tisa-cel, although more toxic, in this group of refractory patients according to SCHOLAR-1 criteria. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Formula: C16H21Cl2N3O2).
4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. The solubility of imidazoles in ethers is lower than that in alcohols and decreases with increasing chain length of the ethers . In contrast, the solubility of benzimidazoles in alcohols (C3–C6) is higher than in water and generally decreases with a Imidazole also acts as a microtubule destabilizing agents and inhibits topoisomerase and Cytochrome P450 Family 26 Subfamily A Member 1 (CYP26A1) enzymes.Formula: C16H21Cl2N3O2
Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem